
Biologics Contract Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Afri
Description
The global biologics contract manufacturing industry is witnessing accelerated momentum, driven by an expanding pipeline of complex biologics, biosimilars, and next-generation therapies. As pharmaceutical and biotech companies increasingly outsource production to optimize efficiency, reduce costs, and scale faster, contract development and manufacturing organizations (CDMOs) are emerging as indispensable partners.
Market Insights
The biologics contract manufacturing market is projected to grow significantly, from a valuation of USD 21.9 billion in 2025 to USD 40.2 billion by 2032, expanding at a robust CAGR of 9.03% during the forecast period. The surge is propelled by a growing need for advanced manufacturing platforms, cost-effective production methods, and specialized services that support the lifecycle of complex biologics.
Key Market Drivers
• Strong Pipeline of Biologics: With over 1,500 biomolecules under development for more than 100 diseases, the biologics Analysis is thriving. The success rate of biologics continues to surpass that of small-molecule drugs, prompting more investment and outsourcing.
• Capacity Constraints: Limited internal production capabilities among major pharmaceutical companies are driving the need to contract CDMOs, especially as demand for high-quality biologics increases.
• Next-Generation Therapeutics: The growing focus on monoclonal and bispecific antibodies, cell and gene therapies, and recombinant proteins is spurring demand for advanced manufacturing capabilities.
• Technological Evolution: The adoption of single-use bioreactors, automation, and modular manufacturing systems enhances flexibility, reduces operational time, and supports scalability, giving CDMOs a competitive edge.
Business Opportunities
CDMOs offering integrated, end-to-end services—from early-stage development through to commercial manufacturing—are gaining a strategic advantage. With a rising preference for “one-stop-shop” providers, companies that offer molecule-to-market solutions are in high demand. This trend is amplified by increasing outsourcing in the later stages of clinical development to reduce risk and accelerate product commercialization.
Major industry players are also actively expanding their footprints through mergers, acquisitions, and partnerships. For example, CDMOs like Lonza and AGC Biologics have strengthened their service portfolios and global reach through targeted acquisitions and collaborations.
Regional Highlights
• United States: The U.S. continues to dominate the North American market, backed by a strong innovation ecosystem, leading biotech firms, and significant venture capital investments in R&D. A high concentration of CDMOs and research institutions further bolsters market growth.
• Germany: In Europe, Germany stands out due to its well-established research infrastructure and increasing preference for outsourced biopharma services to cut costs and improve time-to-market.
• China: China is rapidly emerging as a key market, supported by its growing skilled workforce, strong governmental backing, and increasing international collaborations with local manufacturers.
Competitive Analysis
The biologics contract manufacturing market is characterized by intense competition, with key players expanding service offerings, upgrading infrastructure, and strengthening global networks. Leading companies include:
• Lonza Group AG
• Samsung Biologics
• WuXi Biologics
• Fujifilm Diosynth Biotechnologies
• Boehringer Ingelheim (BioXcellence)
• AbbVie CM
• Patheon (Thermo Fisher Scientific)
• AGC Biologics
• Avid Bioservices
• Catalent Inc.
• Emergent BioSolutions
• Ajinomoto Bio-Pharma
• KBI Biopharma
• Rentschler Biotechnologie GmbH
• Abzena plc
• ProBioGen AG
• Novasep
• Therapure Biopharma Inc.
These companies are actively investing in R&D, expanding production capacity, and forming alliances to capture a larger share of the growing market.
Challenges
Despite its growth, the market faces headwinds including regulatory complexities, stringent compliance requirements, and shortages of skilled talent in emerging economies. New entrants often find high capital requirements and complex approval pathways challenging, limiting the participation of small and mid-sized enterprises.
Market Segmentation
By Product
• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Insulin
• Interferons
• Growth Factors
• Others
By Platform
• Mammalian
• Microbial
By Therapeutic Area
• Oncology
• Autoimmune Diseases
• Metabolic Diseases
• Cardiovascular Diseases
• Infectious Diseases
• Neurology
• Ophthalmology
• Respiratory Disorders
• Others
By Application
• Commercial
• Clinical
By Region
• North America
• Europe
• Latin America
• East Asia
• South Asia
• Oceania
• Middle East & Africa
Please note: Delivery Timelines - 5 working days.
Market Insights
The biologics contract manufacturing market is projected to grow significantly, from a valuation of USD 21.9 billion in 2025 to USD 40.2 billion by 2032, expanding at a robust CAGR of 9.03% during the forecast period. The surge is propelled by a growing need for advanced manufacturing platforms, cost-effective production methods, and specialized services that support the lifecycle of complex biologics.
Key Market Drivers
• Strong Pipeline of Biologics: With over 1,500 biomolecules under development for more than 100 diseases, the biologics Analysis is thriving. The success rate of biologics continues to surpass that of small-molecule drugs, prompting more investment and outsourcing.
• Capacity Constraints: Limited internal production capabilities among major pharmaceutical companies are driving the need to contract CDMOs, especially as demand for high-quality biologics increases.
• Next-Generation Therapeutics: The growing focus on monoclonal and bispecific antibodies, cell and gene therapies, and recombinant proteins is spurring demand for advanced manufacturing capabilities.
• Technological Evolution: The adoption of single-use bioreactors, automation, and modular manufacturing systems enhances flexibility, reduces operational time, and supports scalability, giving CDMOs a competitive edge.
Business Opportunities
CDMOs offering integrated, end-to-end services—from early-stage development through to commercial manufacturing—are gaining a strategic advantage. With a rising preference for “one-stop-shop” providers, companies that offer molecule-to-market solutions are in high demand. This trend is amplified by increasing outsourcing in the later stages of clinical development to reduce risk and accelerate product commercialization.
Major industry players are also actively expanding their footprints through mergers, acquisitions, and partnerships. For example, CDMOs like Lonza and AGC Biologics have strengthened their service portfolios and global reach through targeted acquisitions and collaborations.
Regional Highlights
• United States: The U.S. continues to dominate the North American market, backed by a strong innovation ecosystem, leading biotech firms, and significant venture capital investments in R&D. A high concentration of CDMOs and research institutions further bolsters market growth.
• Germany: In Europe, Germany stands out due to its well-established research infrastructure and increasing preference for outsourced biopharma services to cut costs and improve time-to-market.
• China: China is rapidly emerging as a key market, supported by its growing skilled workforce, strong governmental backing, and increasing international collaborations with local manufacturers.
Competitive Analysis
The biologics contract manufacturing market is characterized by intense competition, with key players expanding service offerings, upgrading infrastructure, and strengthening global networks. Leading companies include:
• Lonza Group AG
• Samsung Biologics
• WuXi Biologics
• Fujifilm Diosynth Biotechnologies
• Boehringer Ingelheim (BioXcellence)
• AbbVie CM
• Patheon (Thermo Fisher Scientific)
• AGC Biologics
• Avid Bioservices
• Catalent Inc.
• Emergent BioSolutions
• Ajinomoto Bio-Pharma
• KBI Biopharma
• Rentschler Biotechnologie GmbH
• Abzena plc
• ProBioGen AG
• Novasep
• Therapure Biopharma Inc.
These companies are actively investing in R&D, expanding production capacity, and forming alliances to capture a larger share of the growing market.
Challenges
Despite its growth, the market faces headwinds including regulatory complexities, stringent compliance requirements, and shortages of skilled talent in emerging economies. New entrants often find high capital requirements and complex approval pathways challenging, limiting the participation of small and mid-sized enterprises.
Market Segmentation
By Product
• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Insulin
• Interferons
• Growth Factors
• Others
By Platform
• Mammalian
• Microbial
By Therapeutic Area
• Oncology
• Autoimmune Diseases
• Metabolic Diseases
• Cardiovascular Diseases
• Infectious Diseases
• Neurology
• Ophthalmology
• Respiratory Disorders
• Others
By Application
• Commercial
• Clinical
By Region
• North America
• Europe
• Latin America
• East Asia
• South Asia
• Oceania
• Middle East & Africa
Please note: Delivery Timelines - 5 working days.
Table of Contents
207 Pages
- 1. Executive Summary
- 1.1. Global Biologics Contract Manufacturing Demand Market Snapshot
- 1.2. Future Projections
- 1.3. Key Market Trends
- 1.4. Regional Snapshot, by Value and Volume, 2025
- 1.5. Analyst Recommendations
- 2. Market Overview
- 2.1. Market Definitions and Segmentations
- 2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
- 2.3. Value Chain Analysis
- 2.4. Porter’s Five Forces Analysis
- 2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
- 2.6. Impact of Ukraine-Russia Conflict
- 2.7. Economic Overview
- 2.7.1. World Economic Projections
- 2.8. PESTLE Analysis
- 3. Production Output and Trade Statistics, 2019-2024
- 3.1. Global Biologics Contract Manufacturing Demand Market Production Output, by Region, Value (US$ Bn) and Volume (KL), 2019-2024
- 3.1.1. North America
- 3.1.2. Europe
- 3.1.3. Asia Pacific
- 3.1.4. Latin America
- 3.1.5. Middle East and Africa
- 4. Price Analysis, 2019-2024
- 4.1. Global Average Price Analysis, by Product, US$ Per Unit, 2019-2024
- 4.2. Prominent Factor Affecting Protective Sunglasses Prices
- 4.3. Global Average Price Analysis, by Region, US$ Per Unit
- 5. Global Biologics Contract Manufacturing Demand Market Outlook, 2019-2032
- 5.1. Global Biologics Contract Manufacturing Demand Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 5.1.1. Key Highlights
- 5.1.1.1. Monoclonal Antibodies
- 5.1.1.2. Recombinant Proteins
- 5.1.1.3. Vaccines
- 5.1.1.4. Insulin
- 5.1.1.5. Interferons
- 5.1.1.6. Growth Factors
- 5.1.1.7. Others
- 5.2. Global Biologics Contract Manufacturing Demand Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2032
- 5.2.1. Key Highlights
- 5.2.1.1. Mammalian
- 5.2.1.2. Microbial
- 5.3. Global Biologics Contract Manufacturing Demand Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2032
- 5.3.1. Key Highlights
- 5.3.1.1. Oncology
- 5.3.1.2. Autoimmune Disease
- 5.3.1.3. Metabolic Disease
- 5.3.1.4. Opthalmology
- 5.3.1.5. Cardiovascular Disease
- 5.3.1.6. Infectious Disease
- 5.3.1.7. Neurology
- 5.3.1.8. Respiratory Disorder
- 5.3.1.9. Others
- 5.4. Global Biologics Contract Manufacturing Demand Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2032
- 5.4.1. Key Highlights
- 5.4.1.1. Commercial
- 5.4.1.2. Clinical
- 5.5. Global Biologics Contract Manufacturing Demand Market Outlook, by Region, Value (US$ Bn) and Volume (KL), 2019-2032
- 5.5.1. Key Highlights
- 5.5.1.1. North America
- 5.5.1.2. Europe
- 5.5.1.3. Asia Pacific
- 5.5.1.4. Latin America
- 5.5.1.5. Middle East & Africa
- 6. North America Biologics Contract Manufacturing Demand Market Outlook, 2019-2032
- 6.1. North America Biologics Contract Manufacturing Demand Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 6.1.1. Key Highlights
- 6.1.1.1. Monoclonal Antibodies
- 6.1.1.2. Recombinant Proteins
- 6.1.1.3. Vaccines
- 6.1.1.4. Insulin
- 6.1.1.5. Interferons
- 6.1.1.6. Growth Factors
- 6.1.1.7. Others
- 6.2. North America Biologics Contract Manufacturing Demand Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2032
- 6.2.1. Key Highlights
- 6.2.1.1. Mammalian
- 6.2.1.2. Microbial
- 6.3. North America Biologics Contract Manufacturing Demand Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2032
- 6.3.1. Key Highlights
- 6.3.1.1. Oncology
- 6.3.1.2. Autoimmune Disease
- 6.3.1.3. Metabolic Disease
- 6.3.1.4. Opthalmology
- 6.3.1.5. Cardiovascular Disease
- 6.3.1.6. Infectious Disease
- 6.3.1.7. Neurology
- 6.3.1.8. Respiratory Disorder
- 6.3.1.9. Others
- 6.4. North America Biologics Contract Manufacturing Demand Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2032
- 6.4.1. Key Highlights
- 6.4.1.1. Commercial
- 6.4.1.2. Clinical
- 6.5. North America Biologics Contract Manufacturing Demand Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2032
- 6.5.1. Key Highlights
- 6.5.1.1. U.S. Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 6.5.1.2. U.S. Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
- 6.5.1.3. U.S. Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
- 6.5.1.4. U.S. Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
- 6.5.1.5. Canada Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 6.5.1.6. Canada Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
- 6.5.1.7. Canada Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
- 6.5.1.8. Canada Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
- 6.5.2. BPS Analysis/Market Attractiveness Analysis
- 7. Europe Biologics Contract Manufacturing Demand Market Outlook, 2019-2032
- 7.1. Europe Biologics Contract Manufacturing Demand Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.1.1. Key Highlights
- 7.1.1.1. Monoclonal Antibodies
- 7.1.1.2. Recombinant Proteins
- 7.1.1.3. Vaccines
- 7.1.1.4. Insulin
- 7.1.1.5. Interferons
- 7.1.1.6. Growth Factors
- 7.1.1.7. Others
- 7.2. Europe Biologics Contract Manufacturing Demand Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.2.1. Key Highlights
- 7.2.1.1. Mammalian
- 7.2.1.2. Microbial
- 7.3. Europe Biologics Contract Manufacturing Demand Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.3.1. Key Highlights
- 7.3.1.1. Oncology
- 7.3.1.2. Autoimmune Disease
- 7.3.1.3. Metabolic Disease
- 7.3.1.4. Opthalmology
- 7.3.1.5. Cardiovascular Disease
- 7.3.1.6. Infectious Disease
- 7.3.1.7. Neurology
- 7.3.1.8. Respiratory Disorder
- 7.3.1.9. Others
- 7.4. Europe Biologics Contract Manufacturing Demand Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.4.1. Key Highlights
- 7.4.1.1. Commercial
- 7.4.1.2. Clinical
- 7.5. Europe Biologics Contract Manufacturing Demand Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1. Key Highlights
- 7.5.1.1. Germany Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1.2. Germany Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1.3. Germany Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1.4. Germany Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1.5. U.K. Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1.6. U.K. Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1.7. U.K. Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1.8. U.K. Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1.9. France Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1.10. France Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1.11. France Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1.12. France Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1.13. Italy Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1.14. Italy Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1.15. Italy Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1.16. Italy Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1.17. Turkey Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1.18. Turkey Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1.19. Turkey Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1.20. Turkey Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1.21. Russia Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1.22. Russia Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1.23. Russia Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1.24. Russia Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1.25. Rest of Europe Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1.26. Rest of Europe Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1.27. Rest of Europe Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.1.28. Rest of Europe Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
- 7.5.2. BPS Analysis/Market Attractiveness Analysis
- 8. Asia Pacific Biologics Contract Manufacturing Demand Market Outlook, 2019-2032
- 8.1. Asia Pacific Biologics Contract Manufacturing Demand Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.1.1. Key Highlights
- 8.1.1.1. Monoclonal Antibodies
- 8.1.1.2. Recombinant Proteins
- 8.1.1.3. Vaccines
- 8.1.1.4. Insulin
- 8.1.1.5. Interferons
- 8.1.1.6. Growth Factors
- 8.1.1.7. Others
- 8.2. Asia Pacific Biologics Contract Manufacturing Demand Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.2.1. Key Highlights
- 8.2.1.1. Mammalian
- 8.2.1.2. Microbial
- 8.3. Asia Pacific Biologics Contract Manufacturing Demand Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.3.1. Key Highlights
- 8.3.1.1. Oncology
- 8.3.1.2. Autoimmune Disease
- 8.3.1.3. Metabolic Disease
- 8.3.1.4. Opthalmology
- 8.3.1.5. Cardiovascular Disease
- 8.3.1.6. Infectious Disease
- 8.3.1.7. Neurology
- 8.3.1.8. Respiratory Disorder
- 8.3.1.9. Others
- 8.4. Asia Pacific Biologics Contract Manufacturing Demand Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.4.1. Key Highlights
- 8.4.1.1. Commercial
- 8.4.1.2. Clinical
- 8.5. Asia Pacific Biologics Contract Manufacturing Demand Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.5.1. Key Highlights
- 8.5.1.1. China Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.5.1.2. China Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.5.1.3. China Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.5.1.4. China Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.5.1.5. Japan Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.5.1.6. Japan Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.5.1.7. Japan Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.5.1.8. Japan Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.5.1.9. South Korea Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.5.1.10. South Korea Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.5.1.11. South Korea Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.5.1.12. South Korea Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.5.1.13. India Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.5.1.14. India Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.5.1.15. India Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.5.1.16. India Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.5.1.17. Southeast Asia Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.5.1.18. Southeast Asia Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.5.1.19. Southeast Asia Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.5.1.20. Southeast Asia Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.5.1.21. Rest of Asia Pacific Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.5.1.22. Rest of Asia Pacific Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.5.1.23. Rest of Asia Pacific Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.5.1.24. Rest of Asia Pacific Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
- 8.5.2. BPS Analysis/Market Attractiveness Analysis
- 9. Latin America Biologics Contract Manufacturing Demand Market Outlook, 2019-2032
- 9.1. Latin America Biologics Contract Manufacturing Demand Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 9.1.1. Key Highlights
- 9.1.1.1. Monoclonal Antibodies
- 9.1.1.2. Recombinant Proteins
- 9.1.1.3. Vaccines
- 9.1.1.4. Insulin
- 9.1.1.5. Interferons
- 9.1.1.6. Growth Factors
- 9.1.1.7. Others
- 9.2. Latin America Biologics Contract Manufacturing Demand Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2032
- 9.2.1.1. Mammalian
- 9.2.1.2. Microbial
- 9.3. Latin America Biologics Contract Manufacturing Demand Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2032
- 9.3.1. Key Highlights
- 9.3.1.1. Oncology
- 9.3.1.2. Autoimmune Disease
- 9.3.1.3. Metabolic Disease
- 9.3.1.4. Opthalmology
- 9.3.1.5. Cardiovascular Disease
- 9.3.1.6. Infectious Disease
- 9.3.1.7. Neurology
- 9.3.1.8. Respiratory Disorder
- 9.3.1.9. Others
- 9.4. Latin America Biologics Contract Manufacturing Demand Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2032
- 9.4.1. Key Highlights
- 9.4.1.1. Commercial
- 9.4.1.2. Clinical
- 9.5. Latin America Biologics Contract Manufacturing Demand Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2032
- 9.5.1. Key Highlights
- 9.5.1.1. Brazil Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 9.5.1.2. Brazil Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
- 9.5.1.3. Brazil Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
- 9.5.1.4. Brazil Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
- 9.5.1.5. Mexico Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 9.5.1.6. Mexico Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
- 9.5.1.7. Mexico Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
- 9.5.1.8. Mexico Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
- 9.5.1.9. Argentina Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 9.5.1.10. Argentina Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
- 9.5.1.11. Argentina Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
- 9.5.1.12. Argentina Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
- 9.5.1.13. Rest of Latin America Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 9.5.1.14. Rest of Latin America Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
- 9.5.1.15. Rest of Latin America Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
- 9.5.1.16. Rest of Latin America Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
- 9.5.2. BPS Analysis/Market Attractiveness Analysis
- 10. Middle East & Africa Biologics Contract Manufacturing Demand Market Outlook, 2019-2032
- 10.1. Middle East & Africa Biologics Contract Manufacturing Demand Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 10.1.1. Key Highlights
- 10.1.1.1. Monoclonal Antibodies
- 10.1.1.2. Recombinant Proteins
- 10.1.1.3. Vaccines
- 10.1.1.4. Insulin
- 10.1.1.5. Interferons
- 10.1.1.6. Growth Factors
- 10.1.1.7. Others
- 10.2. Middle East & Africa Biologics Contract Manufacturing Demand Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2032
- 10.2.1. Key Highlights
- 10.2.1.1. Mammalian
- 10.2.1.2. Microbial
- 10.3. Middle East & Africa Biologics Contract Manufacturing Demand Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2032
- 10.3.1. Key Highlights
- 10.3.1.1. Oncology
- 10.3.1.2. Autoimmune Disease
- 10.3.1.3. Metabolic Disease
- 10.3.1.4. Opthalmology
- 10.3.1.5. Cardiovascular Disease
- 10.3.1.6. Infectious Disease
- 10.3.1.7. Neurology
- 10.3.1.8. Respiratory Disorder
- 10.3.1.9. Others
- 10.4. Middle East & Africa Biologics Contract Manufacturing Demand Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2032
- 10.4.1. Key Highlights
- 10.4.1.1. Commercial
- 10.4.1.2. Clinical
- 10.5. Middle East & Africa Biologics Contract Manufacturing Demand Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2032
- 10.5.1. Key Highlights
- 10.5.1.1. GCC Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 10.5.1.2. GCC Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
- 10.5.1.3. GCC Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
- 10.5.1.4. GCC Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
- 10.5.1.5. South Africa Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 10.5.1.6. South Africa Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
- 10.5.1.7. South Africa Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
- 10.5.1.8. South Africa Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
- 10.5.1.9. Egypt Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 10.5.1.10. Egypt Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
- 10.5.1.11. Egypt Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
- 10.5.1.12. Egypt Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
- 10.5.1.13. Nigeria Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 10.5.1.14. Nigeria Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
- 10.5.1.15. Nigeria Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
- 10.5.1.16. Nigeria Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
- 10.5.1.17. Rest of Middle East & Africa Biologics Contract Manufacturing Demand Market by Product, Value (US$ Bn) and Volume (KL), 2019-2032
- 10.5.1.18. Rest of Middle East & Africa Biologics Contract Manufacturing Demand Market Indication, Value (US$ Bn) and Volume (KL), 2019-2032
- 10.5.1.19. Rest of Middle East & Africa Biologics Contract Manufacturing Demand Market Artery Type, Value (US$ Bn) and Volume (KL), 2019-2032
- 10.5.1.20. Rest of Middle East & Africa Biologics Contract Manufacturing Demand Market End User, Value (US$ Bn) and Volume (KL), 2019-2032
- 10.5.2. BPS Analysis/Market Attractiveness Analysis
- 11. Competitive Landscape
- 11.1. Artery Type vs Indication Heatmap
- 11.2. Manufacturer vs Indication Heatmap
- 11.3. Company Market Share Analysis, 2025
- 11.4. Competitive Dashboard
- 11.5. Company Profiles
- 11.5.1. Samsung Biologics
- 11.5.1.1. Company Overview
- 11.5.1.2. Product Portfolio
- 11.5.1.3. Financial Overview
- 11.5.1.4. Business Strategies and Development
- 11.5.2. BioXcellence (Boehringer Ingelheim)
- 11.5.2.1. Company Overview
- 11.5.2.2. Product Portfolio
- 11.5.2.3. Financial Overview
- 11.5.2.4. Business Strategies and Development
- 11.5.3. Lonza Group AG
- 11.5.3.1. Company Overview
- 11.5.3.2. Product Portfolio
- 11.5.3.3. Financial Overview
- 11.5.3.4. Business Strategies and Development
- 11.5.4. Fujifilm Diosynth Biotechnologies
- 11.5.4.1. Company Overview
- 11.5.4.2. Product Portfolio
- 11.5.4.3. Financial Overview
- 11.5.4.4. Business Strategies and Development
- 11.5.5. AbbVie CM (AbbVie Inc.)
- 11.5.5.1. Company Overview
- 11.5.5.2. Product Portfolio
- 11.5.5.3. Financial Overview
- 11.5.5.4. Business Strategies and Development
- 11.5.6. WuXi Biologics (Cayman) Inc.
- 11.5.6.1. Company Overview
- 11.5.6.2. Product Portfolio
- 11.5.6.3. Financial Overview
- 11.5.6.4. Business Strategies and Development
- 11.5.7. AGC Biologics
- 11.5.7.1. Company Overview
- 11.5.7.2. Product Portfolio
- 11.5.7.3. Financial Overview
- 11.5.7.4. Business Strategies and Development
- 11.5.8. Patheon N.V. (Thermo Fisher Scientific Inc.)
- 11.5.8.1. Company Overview
- 11.5.8.2. Product Portfolio
- 11.5.8.3. Financial Overview
- 11.5.8.4. Business Strategies and Development
- 11.5.9. Emergent BioSolutions Inc.
- 11.5.9.1. Company Overview
- 11.5.9.2. Product Portfolio
- 11.5.9.3. Financial Overview
- 11.5.9.4. Business Strategies and Development
- 11.5.10. Ajinomoto Bio-Pharma
- 11.5.10.1. Company Overview
- 11.5.10.2. Product Portfolio
- 11.5.10.3. Financial Overview
- 11.5.10.4. Business Strategies and Development
- 11.5.11. Avid Bioservices, Inc.
- 11.5.11.1. Company Overview
- 11.5.11.2. Product Portfolio
- 11.5.11.3. Financial Overview
- 11.5.11.4. Business Strategies and Development
- 11.5.12. KBI Biopharma
- 11.5.12.1. Company Overview
- 11.5.12.2. Product Portfolio
- 11.5.12.3. Financial Overview
- 11.5.12.4. Business Strategies and Development
- 11.5.13. Rentschler Biotechnologie GmbH
- 11.5.13.1. Company Overview
- 11.5.13.2. Product Portfolio
- 11.5.13.3. Financial Overview
- 11.5.13.4. Business Strategies and Development
- 11.5.14. Merck KGaA
- 11.5.14.1. Company Overview
- 11.5.14.2. Product Portfolio
- 11.5.14.3. Financial Overview
- 11.5.14.4. Business Strategies and Development
- 11.5.15. Catalent Inc.
- 11.5.15.1. Company Overview
- 11.5.15.2. Product Portfolio
- 11.5.15.3. Financial Overview
- 11.5.15.4. Business Strategies and Development
- 11.5.16. Therapure Biopharma Inc.
- 11.5.16.1. Company Overview
- 11.5.16.2. Product Portfolio
- 11.5.16.3. Financial Overview
- 11.5.16.4. Business Strategies and Development
- 11.5.17. Novasep
- 11.5.17.1. Company Overview
- 11.5.17.2. Product Portfolio
- 11.5.17.3. Financial Overview
- 11.5.17.4. Business Strategies and Development
- 11.5.18. Abzena plc.
- 11.5.18.1. Company Overview
- 11.5.18.2. Product Portfolio
- 11.5.18.3. Financial Overview
- 11.5.18.4. Business Strategies and Development
- 11.5.19. ProBioGen AG
- 11.5.19.1. Company Overview
- 11.5.19.2. Product Portfolio
- 11.5.19.3. Financial Overview
- 11.5.19.4. Business Strategies and Development
- 12. Appendix
- 12.1. Research Methodology
- 12.2. Report Assumptions
- 12.3. Acronyms and Abbreviations >/DL>
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.